State Street Corp Raises Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

State Street Corp raised its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 3.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,514,721 shares of the company’s stock after purchasing an additional 127,753 shares during the quarter. State Street Corp’s holdings in Amneal Pharmaceuticals were worth $29,242,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Rothschild Investment LLC bought a new position in Amneal Pharmaceuticals during the 2nd quarter valued at $26,000. Gladius Capital Management LP acquired a new stake in Amneal Pharmaceuticals in the third quarter worth $37,000. DekaBank Deutsche Girozentrale bought a new stake in Amneal Pharmaceuticals in the 2nd quarter valued at about $42,000. nVerses Capital LLC acquired a new position in shares of Amneal Pharmaceuticals during the second quarter worth approximately $62,000. Finally, Xponance Inc. bought a new position in shares of Amneal Pharmaceuticals in the second quarter worth $65,000. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on AMRX. StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price for the company in a report on Friday, September 6th. Truist Financial boosted their price objective on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, October 2nd. Finally, Piper Sandler upped their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Amneal Pharmaceuticals Trading Up 0.4 %

Shares of AMRX stock opened at $7.78 on Friday. The firm’s 50 day moving average is $8.42 and its 200-day moving average is $7.94. Amneal Pharmaceuticals, Inc. has a 1 year low of $5.01 and a 1 year high of $9.48. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -11.44 and a beta of 1.12.

Insider Buying and Selling

In related news, SVP Jason B. Daly sold 43,657 shares of the stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $8.61, for a total transaction of $375,886.77. Following the completion of the sale, the senior vice president now directly owns 13,665 shares of the company’s stock, valued at approximately $117,655.65. This represents a 76.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 26.56% of the stock is currently owned by insiders.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.